icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria †april 22-26
Back grey_arrow_rt.gif
 
 
 
Reduction in Annual Medical Costs with Early Treatment of HCV Using Abbvie 3D
(AbT-450/Ritonavir/Ombitasvir and Dasabuvir) ± Ribavirin in the United States

 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
SJ Johnson1, JC Samp2, TR Juday2, SE Marx2, H Parisť1, S virabhak1, S Saab3 1Medicus Economics, Milton, 2Global Health Economics and Outcomes Research, Abbvie, Mettawa, 3Pfleger Liver Institute, Los Angeles, United States

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif

EASL8.gif